The latest announcement is out from Relmada Therapeutics ( (RLMD) ).
On April 28, 2025, Relmada Therapeutics announced positive initial data from its Phase 2 study of NDV-01, a novel delivery formulation for treating non-muscle invasive bladder cancer, at the American Urology Association 2025 Annual Meeting. The study showed that 90% of patients achieved high-grade disease-free status, demonstrating strong clinical activity and supporting further development of NDV-01. The treatment was well tolerated with no significant adverse events, suggesting a promising future for NDV-01 as a potential class-leading therapy for NMIBC.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
Relmada Therapeutics’ stock is currently speculative, characterized by significant financial challenges including zero revenue and high cash burn. While recent strategic acquisitions and pipeline developments offer potential for future growth, the current financial performance and valuation indicate high risk. Technical analysis suggests short-term momentum, but volatility remains a concern.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies with the potential to provide significant clinical benefits to targeted patient populations. Their lead investigational program, NDV-01, is being evaluated for the treatment of High-Grade Non-Muscle Invasive Bladder Cancer.
YTD Price Performance: 43.33%
Average Trading Volume: 1,837,408
Technical Sentiment Signal: Buy
Current Market Cap: $21.41M
Learn more about RLMD stock on TipRanks’ Stock Analysis page.